All articles by GlobalData Healthcare

WHO analysis shows four in ten cancers could be prevented

Globally, cancer is a leading cause of death and presents a significant challenge to public health. Despite major therapeutic advances…
Leishmaniasis on World NTD Day: persistent pockets in a low-incidence era

World Neglected Tropical Disease (NTD) Day is an opportunity to highlight leishmaniasis not only as an ongoing health challenge, but…
Vitamin D deficiency increases the risk of respiratory tract infection

Respiratory tract infections (RTIs) are widely prevalent and cause significant morbidity and mortality globally. RTIs are broadly divided into upper…
Clearing the air: investigating the association between breast cancer and air pollution

Breast cancer is the second most common type of cancer in women, according to the Mayo Clinic, and while survival…
Study finds no link between paracetamol use in pregnancy and autism risk

According to the World Health Organization, approximately one in 127 individuals worldwide had autism spectrum disorder (ASD) in 2021. ASD…

New data links eczema to inflammatory bowel and eye conditions

Eczema, also known as dermatitis, is a skin condition characterised by dry, itchy, and inflamed skin. Its symptoms can impact…
Meta-analysis confirms nephroprotective benefits of ERAs

A recent research study, conducted by Shi and colleagues and published in the Clinical Journal of the American Society of…
JPM26: Immunocore Signals Entry into Type 1 Diabetes

At the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on 14th January 2026, Immunocore outlined 2026 strategic priorities…
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens

At the 44th Annual J.P. Morgan Healthcare Conference, Atea Pharmaceuticals outlined its strategy for hepatitis C virus (HCV), showcasing its…
JPM26: Leo Pharma’s growth strategy puts a spotlight on rare dermatology diseases

Leo Pharma’s bold commitment to be a strong player in the dermatological space was made clear at the JP Morgan…